Loading
Life sciences · Journal article
Frontiers in Oncology · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metastatic dissemination and therapeutic failure, the major determinants of breast cancer mortality, are fundamentally driven by epithelial-mesenchymal transition (EMT) and its phenotypic plasticity. This review comprehensively interrogates the regulatory logic of EMT plasticity in breast cancer, decoding the intricate interplay among transcription factor cascades, epigenetic landscapes, non-coding RNA circuits, and microenvironmental cues that collectively sustain tumor cell adaptability. We further delineate the translational frontier, summarizing recent advances in pharmacologically targeting EMT core regulators and discussing the promise and pitfalls of plasticity-modulating therapeutic paradigms. Ultimately, by integrating evolving knowledge from basic and translational research, we present a cohesive framework aimed at bridging mechanistic understanding with clinical decision-making, with the goal of refining precision therapy for breast cancer patients.